NCT02512172View on ClinicalTrials.gov

A Study of Enhancing Response to MK-3475 in Advanced Colorectal Cancer

PHASE1CompletedINTERVENTIONAL

Enrollment

27

Participants

Timeline

Start Date

February 19, 2016

Primary Completion Date

November 20, 2021

Study Completion Date

November 20, 2021

Conditions

Colorectal Cancer

Interventions

DRUG

Oral CC-486

DRUG

Romidepsin

DRUG

MK-3475

Trial Locations (1)

21205

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore

Sponsors

Collaborators (1)

Celgene Corporation

All Listed Sponsors

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

collaborator

Celgene Corporation

INDUSTRY

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER